147 related articles for article (PubMed ID: 27780333)
1. Persistence in Therapy With Risperidone and Aripiprazole in Pediatric Outpatients: A 2-Year Naturalistic Comparison.
Pozzi M; Pisano S; Bertella S; Capuano A; Rizzo R; Antoniazzi S; Auricchio F; Carnovale C; Cattaneo D; Ferrajolo C; Gentili M; Guastella G; Mani E; Rafaniello C; Riccio MP; Scuderi MG; Sperandeo S; Sportiello L; Villa L; Radice S; Clementi E; Rossi F; Pascotto A; Bernardini R; Molteni M; Bravaccio C
J Clin Psychiatry; 2016 Dec; 77(12):e1601-e1609. PubMed ID: 27780333
[TBL] [Abstract][Full Text] [Related]
2. Antipsychotic Treatment Effectiveness in First Episode of Psychosis: PAFIP 3-Year Follow-Up Randomized Clinical Trials Comparing Haloperidol, Olanzapine, Risperidone, Aripiprazole, Quetiapine, and Ziprasidone.
Gómez-Revuelta M; Pelayo-Terán JM; Juncal-Ruiz M; Vázquez-Bourgon J; Suárez-Pinilla P; Romero-Jiménez R; Setién Suero E; Ayesa-Arriola R; Crespo-Facorro B
Int J Neuropsychopharmacol; 2020 Apr; 23(4):217-229. PubMed ID: 31974576
[TBL] [Abstract][Full Text] [Related]
3. Risk of discontinuation of atypical antipsychotic agents in the treatment of schizophrenia.
Mullins CD; Obeidat NA; Cuffel BJ; Naradzay J; Loebel AD
Schizophr Res; 2008 Jan; 98(1-3):8-15. PubMed ID: 17596914
[TBL] [Abstract][Full Text] [Related]
4. A Randomized Comparison of Aripiprazole and Risperidone for the Acute Treatment of First-Episode Schizophrenia and Related Disorders: 3-Month Outcomes.
Robinson DG; Gallego JA; John M; Petrides G; Hassoun Y; Zhang JP; Lopez L; Braga RJ; Sevy SM; Addington J; Kellner CH; Tohen M; Naraine M; Bennett N; Greenberg J; Lencz T; Correll CU; Kane JM; Malhotra AK
Schizophr Bull; 2015 Nov; 41(6):1227-36. PubMed ID: 26338693
[TBL] [Abstract][Full Text] [Related]
5. An open, large, 6-month naturalistic study of outcome in schizophrenic outpatients, treated with olanzapine.
Krzystanek M; Krupka-Matuszczyk I
Hum Psychopharmacol; 2011 Jan; 26(1):81-5. PubMed ID: 23055416
[TBL] [Abstract][Full Text] [Related]
6. Second generation antipsychotics in 'real-life' paediatric patients. Adverse drug reactions and clinical outcomes of drug switch.
Rafaniello C; Pozzi M; Pisano S; Ferrajolo C; Bertella S; Sportiello L; Carnovale C; Sullo MG; Cattaneo D; Gentili M; Rizzo R; Pascotto A; Mani E; Villa L; Riccio MP; Sperandeo S; Bernardini R; Bravaccio C; Clementi E; Molteni M; Rossi F; Radice S; Capuano A
Expert Opin Drug Saf; 2016 Dec; 15(sup2):1-8. PubMed ID: 27875914
[TBL] [Abstract][Full Text] [Related]
7. Activating and Tranquilizing Effects of First-Time Treatment with Aripiprazole, Olanzapine, Quetiapine, and Risperidone in Youth.
Al-Dhaher Z; Kapoor S; Saito E; Krakower S; David L; Ake T; Kane JM; Correll CU; Carbon M
J Child Adolesc Psychopharmacol; 2016 Jun; 26(5):458-70. PubMed ID: 27093218
[TBL] [Abstract][Full Text] [Related]
8. Off-label second generation antipsychotics for impulse regulation disorders: a review.
Scheltema Beduin A; de Haan L
Psychopharmacol Bull; 2010; 43(3):45-81. PubMed ID: 21150846
[TBL] [Abstract][Full Text] [Related]
9. Antipsychotic treatment discontinuation in previously untreated patients with schizophrenia: 36-month results from the SOHO study.
Haro JM; Novick D; Suarez D; Roca M
J Psychiatr Res; 2009 Jan; 43(3):265-73. PubMed ID: 18644606
[TBL] [Abstract][Full Text] [Related]
10. Effects of aripiprazole on prolactin levels in subjects with schizophrenia during cross-titration with risperidone or olanzapine: analysis of a randomized, open-label study.
Byerly MJ; Marcus RN; Tran QV; Eudicone JM; Whitehead R; Baker RA
Schizophr Res; 2009 Feb; 107(2-3):218-22. PubMed ID: 19038534
[TBL] [Abstract][Full Text] [Related]
11. Patterns of discontinuation of atypical antipsychotics in the province of Québec: A retrospective prescription claims database analysis.
Moisan J; Grégoire JP
Clin Ther; 2010; 32 Suppl 1():S21-31. PubMed ID: 20152549
[TBL] [Abstract][Full Text] [Related]
12. Therapeutic drug monitoring of second-generation antipsychotics in pediatric patients: an observational study in real-life settings.
Pozzi M; Cattaneo D; Baldelli S; Fucile S; Capuano A; Bravaccio C; Sportiello L; Bertella S; Auricchio F; Bernardini R; Ferrajolo C; Guastella G; Mani E; Carnovale C; Pisano S; Rafaniello C; Riccio MP; Rizzo R; Scuderi MG; Sperandeo S; Villa L; Pascotto A; Molteni M; Rossi F; Radice S; Clementi E
Eur J Clin Pharmacol; 2016 Mar; 72(3):285-93. PubMed ID: 26613956
[TBL] [Abstract][Full Text] [Related]
13. Haloperidol, risperidone, olanzapine and aripiprazole in the management of delirium: A comparison of efficacy, safety, and side effects.
Boettger S; Jenewein J; Breitbart W
Palliat Support Care; 2015 Aug; 13(4):1079-85. PubMed ID: 25191793
[TBL] [Abstract][Full Text] [Related]
14. [A naturalistic, observational study of outpatients with schizophrenia: efficacy and safety results after 6 months. The International Schizophrenia Outpatient Health Outcomes study, IC-SOHO].
István S; Agoston T; Tamás T; Zoltán J
Neuropsychopharmacol Hung; 2007 Oct; 9(3):115-24. PubMed ID: 18399029
[TBL] [Abstract][Full Text] [Related]
15. Tolerability and safety profile of risperidone in a sample of children and adolescents.
Margari L; Matera E; Craig F; Petruzzelli MG; Palmieri VO; Pastore A; Margari F
Int Clin Psychopharmacol; 2013 Jul; 28(4):177-83. PubMed ID: 23689836
[TBL] [Abstract][Full Text] [Related]
16. Long-term antipsychotic monotherapy for schizophrenia: disease burden and comparative outcomes for patients treated with olanzapine, quetiapine, risperidone, or haloperidol monotherapy in a pan-continental observational study.
Dossenbach M; Pecenak J; Szulc A; Irimia V; Anders M; Logozar-Perkovic D; Peciukaitiene D; Kotler M; Smulevich AB; West TM; Lowry AJ; Treuer T
J Clin Psychiatry; 2008 Dec; 69(12):1901-15. PubMed ID: 19012820
[TBL] [Abstract][Full Text] [Related]
17. Second-generation antipsychotic use in children and adolescents: a six-month prospective cohort study in drug-naïve patients.
Arango C; Giráldez M; Merchán-Naranjo J; Baeza I; Castro-Fornieles J; Alda JA; Martínez-Cantarero C; Moreno C; de Andrés P; Cuerda C; de la Serna E; Correll CU; Fraguas D; Parellada M
J Am Acad Child Adolesc Psychiatry; 2014 Nov; 53(11):1179-90,1190.e1-4. PubMed ID: 25440308
[TBL] [Abstract][Full Text] [Related]
18. ECG parameters in children and adolescents treated with aripiprazole and risperidone.
Germanò E; Italiano D; Lamberti M; Guerriero L; Privitera C; D'Amico G; Siracusano R; Ingrassia M; Spina E; Calabrò MP; Gagliano A
Prog Neuropsychopharmacol Biol Psychiatry; 2014 Jun; 51():23-7. PubMed ID: 24211841
[TBL] [Abstract][Full Text] [Related]
19. Switching to aripiprazole in outpatients with schizophrenia experiencing insufficient efficacy and/or safety/tolerability issues with risperidone: a randomized, multicentre, open-label study.
Ryckmans V; Kahn JP; Modell S; Werner C; McQuade RD; Kerselaers W; Lissens J; Sanchez R
Pharmacopsychiatry; 2009 May; 42(3):114-21. PubMed ID: 19452380
[TBL] [Abstract][Full Text] [Related]
20. Effectiveness of second-generation antipsychotics with acute-phase schizophrenia.
Hatta K; Sato K; Hamakawa H; Takebayashi H; Kimura N; Ochi S; Sudo Y; Asukai N; Nakamura H; Usui C; Kawabata T; Hirata T; Sawa Y
Schizophr Res; 2009 Aug; 113(1):49-55. PubMed ID: 19553086
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
